Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis
Identifieur interne : 006680 ( Istex/Corpus ); précédent : 006679; suivant : 006681Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis
Auteurs : Id O Eill ; C. ScullySource :
- Oral Diseases [ 1354-523X ] ; 2012-10.
Abstract
Oral Diseases (2012) 18, 633–638
Url:
DOI: 10.1111/j.1601-0825.2012.01918.x
Links to Exploration step
ISTEX:DB6C5545E00596F12D13C0D857C8087E054660C4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title><author><name sortKey="O Eill, Id" sort="O Eill, Id" uniqKey="O Eill I" first="Id" last="O Eill">Id O Eill</name><affiliation><mods:affiliation>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France</mods:affiliation></affiliation></author><author><name sortKey="Scully, C" sort="Scully, C" uniqKey="Scully C" first="C" last="Scully">C. Scully</name><affiliation><mods:affiliation>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB6C5545E00596F12D13C0D857C8087E054660C4</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1601-0825.2012.01918.x</idno><idno type="url">https://api.istex.fr/document/DB6C5545E00596F12D13C0D857C8087E054660C4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">006680</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006680</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title><author><name sortKey="O Eill, Id" sort="O Eill, Id" uniqKey="O Eill I" first="Id" last="O Eill">Id O Eill</name><affiliation><mods:affiliation>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France</mods:affiliation></affiliation></author><author><name sortKey="Scully, C" sort="Scully, C" uniqKey="Scully C" first="C" last="Scully">C. Scully</name><affiliation><mods:affiliation>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Oral Diseases</title><title level="j" type="alt">ORAL DISEASES</title><idno type="ISSN">1354-523X</idno><idno type="eISSN">1601-0825</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="633">633</biblScope><biblScope unit="page" to="638">638</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-10">2012-10</date></imprint><idno type="ISSN">1354-523X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1354-523X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Oral Diseases (2012) 18, 633–638</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>orofacial</json:string><json:string>intestinal</json:string><json:string>granulomatosis</json:string><json:string>bowel</json:string><json:string>cheilitis</json:string><json:string>ulceration</json:string><json:string>adalimumab</json:string><json:string>orofacial granulomatosis</json:string><json:string>gastroenterol</json:string><json:string>biologics</json:string><json:string>granulomatous</json:string><json:string>scully</json:string><json:string>oral disease</json:string><json:string>assche</json:string><json:string>mucosal</json:string><json:string>dermatol</json:string><json:string>vegetans</json:string><json:string>bowel disease</json:string><json:string>labial</json:string><json:string>mahadevan</json:string><json:string>infusion</json:string><json:string>oral pathol</json:string><json:string>pyostomatitis vegetans</json:string><json:string>recurrence</json:string><json:string>oral ulceration</json:string><json:string>intestinal disease</json:string><json:string>granulomatous cheilitis</json:string><json:string>world congress</json:string><json:string>biological therapy</json:string><json:string>refractory</json:string><json:string>orofacial disease</json:string><json:string>acad dermatol venereol</json:string><json:string>oral medicine</json:string><json:string>infusion givena</json:string><json:string>ileal resection</json:string><json:string>maintenance therapy</json:string><json:string>london position statement</json:string><json:string>oral diseases</json:string><json:string>pyoderma gangrenosum</json:string><json:string>tumour necrosis factor</json:string><json:string>case reports</json:string><json:string>rapid resolution</json:string><json:string>oral lesions</json:string><json:string>extraintestinal manifestations</json:string><json:string>facial</json:string><json:string>antagonist</json:string><json:string>neutrophilic dermatoses</json:string><json:string>case series</json:string><json:string>cheilitis granulomatosa</json:string><json:string>adverse effects</json:string><json:string>infusion reactions</json:string><json:string>systemic immunosuppression</json:string><json:string>risk factors</json:string><json:string>centre poincare</json:string><json:string>oral manifestations</json:string><json:string>complete resolution</json:string><json:string>such case</json:string><json:string>colitis organisation</json:string><json:string>granulomatous process</json:string><json:string>elliott</json:string></teeft></keywords><author><json:item><name>ID O’Neill</name><affiliations><json:string>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France</json:string></affiliations></json:item><json:item><name>C Scully</name><affiliations><json:string>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>biologics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tumour necrosis factor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>infliximab</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Crohn’s disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>orofacial granulomatosis</value></json:item></subject><articleId><json:string>ODI1918</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><qualityIndicators><score>6.506</score><pdfVersion>1.7</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>32</abstractCharCount><pdfWordCount>4446</pdfWordCount><pdfCharCount>29398</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>5</abstractWordCount></qualityIndicators><title>Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title><genre><json:string>review-article</json:string></genre><host><title>Oral Diseases</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1601-0825</json:string></doi><issn><json:string>1354-523X</json:string></issn><eissn><json:string>1601-0825</json:string></eissn><publisherId><json:string>ODI</json:string></publisherId><volume>18</volume><issue>7</issue><pages><first>633</first><last>638</last><total>6</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>REVIEW ARTICLE</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>dentistry, oral surgery & medicine</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>dentistry</json:string></scienceMetrix></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1111/j.1601-0825.2012.01918.x</json:string></doi><id>DB6C5545E00596F12D13C0D857C8087E054660C4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/DB6C5545E00596F12D13C0D857C8087E054660C4/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/DB6C5545E00596F12D13C0D857C8087E054660C4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/DB6C5545E00596F12D13C0D857C8087E054660C4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2012 John Wiley & Sons A/S</licence></availability><date type="published" when="2012-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title><title level="a" type="short">Biologics: oral Crohn’s and OFG</title><author xml:id="author-0000"><persName><forename type="first">ID</forename><surname>O’Neill</surname></persName><affiliation>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">C</forename><surname>Scully</surname></persName><affiliation>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</affiliation></author><idno type="istex">DB6C5545E00596F12D13C0D857C8087E054660C4</idno><idno type="DOI">10.1111/j.1601-0825.2012.01918.x</idno><idno type="unit">ODI1918</idno><idno type="toTypesetVersion">file:ODI.ODI1918.pdf</idno></analytic><monogr><title level="j" type="main">Oral Diseases</title><title level="j" type="alt">ORAL DISEASES</title><idno type="pISSN">1354-523X</idno><idno type="eISSN">1601-0825</idno><idno type="book-DOI">10.1111/(ISSN)1601-0825</idno><idno type="book-part-DOI">10.1111/odi.2012.18.issue-7</idno><idno type="product">ODI</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="633">633</biblScope><biblScope unit="page" to="638">638</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="italic">Oral Diseases</hi> (2012) <hi rend="bold">18</hi>, 633–638</p><p>Antitumour necrosis factor (TNF‐α) therapy has a potential to benefit patients with oral lesions of Crohn’s disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF‐α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF‐α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk–benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">biologics</term><term xml:id="k2">tumour necrosis factor</term><term xml:id="k3">infliximab</term><term xml:id="k4">Crohn’s disease</term><term xml:id="k5">orofacial granulomatosis</term></keywords><classCode scheme="tocHeading1">Review Article</classCode><classCode scheme="articleCategory">REVIEW ARTICLE</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/DB6C5545E00596F12D13C0D857C8087E054660C4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1601-0825</doi><issn type="print">1354-523X</issn><issn type="electronic">1601-0825</issn><idGroup><id type="product" value="ODI"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ORAL DISEASES">Oral Diseases</title></titleGroup></publicationMeta><publicationMeta level="part" position="10107"><doi origin="wiley">10.1111/odi.2012.18.issue-7</doi><numberingGroup><numbering type="journalVolume" number="18">18</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="2012-10">October 2012</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="2" status="forIssue"><doi origin="wiley">10.1111/j.1601-0825.2012.01918.x</doi><idGroup><id type="unit" value="ODI1918"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Review Article</title><title type="articleCategory">REVIEW ARTICLE</title></titleGroup><copyright>© 2012 John Wiley & Sons A/S</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.1.6 mode:FullText" date="2012-09-11"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-03-15"></event><event type="firstOnline" date="2012-03-15"></event><event type="publishedOnlineFinalForm" date="2012-09-11"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-25"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="633">633</numbering><numbering type="pageLast" number="638">638</numbering></numberingGroup><correspondenceTo>Iain D O’Neill, Centre d’Affaires Poincaré, 3 Rue Poincaré, Nice, France. Tel.: +33 952715232, Fax: +33 497071001, E‐mail: <email>iain.oneill@hotmail.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ODI.ODI1918.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 31 January 2012; accepted 11 February 2012</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count></countGroup><titleGroup><title type="main">Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title><title type="shortAuthors">ID O’Neill and C Scully</title><title type="short"><b>Biologics: oral Crohn’s and OFG</b></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>ID</givenNames><familyName>O’Neill</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>C</givenNames><familyName>Scully</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">biologics</keyword><keyword xml:id="k2">tumour necrosis factor</keyword><keyword xml:id="k3">infliximab</keyword><keyword xml:id="k4">Crohn’s disease</keyword><keyword xml:id="k5">orofacial granulomatosis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><i>Oral Diseases</i> (2012) <b>18</b>, 633–638</p><p>Antitumour necrosis factor (TNF‐α) therapy has a potential to benefit patients with oral lesions of Crohn’s disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF‐α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF‐α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk–benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Biologics: oral Crohn’s and OFG</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis</title></titleInfo><name type="personal"><namePart type="given">ID</namePart><namePart type="family">O’Neill</namePart><affiliation>Centre d’Affaires Poincaré, Rue Poincaré, Nice, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Scully</namePart><affiliation>WHO Collaborating Centre for Oral Health‐General Health, Oral Medicine, Bristol</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2012-10</dateIssued><edition>Received 31 January 2012; accepted 11 February 2012</edition><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent></physicalDescription><abstract>Oral Diseases (2012) 18, 633–638</abstract><abstract>Antitumour necrosis factor (TNF‐α) therapy has a potential to benefit patients with oral lesions of Crohn’s disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF‐α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF‐α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk–benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.</abstract><subject lang="en"><genre>keywords</genre><topic>biologics</topic><topic>tumour necrosis factor</topic><topic>infliximab</topic><topic>Crohn’s disease</topic><topic>orofacial granulomatosis</topic></subject><relatedItem type="host"><titleInfo><title>Oral Diseases</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>REVIEW ARTICLE</topic></subject><identifier type="ISSN">1354-523X</identifier><identifier type="eISSN">1601-0825</identifier><identifier type="DOI">10.1111/(ISSN)1601-0825</identifier><identifier type="PublisherID">ODI</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>633</start><end>638</end><total>6</total></extent></part></relatedItem><identifier type="istex">DB6C5545E00596F12D13C0D857C8087E054660C4</identifier><identifier type="DOI">10.1111/j.1601-0825.2012.01918.x</identifier><identifier type="ArticleID">ODI1918</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2012 John Wiley & Sons A/S</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006680 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 006680 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DB6C5545E00596F12D13C0D857C8087E054660C4
|texte= Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis
}}
| This area was generated with Dilib version V0.6.31. |  |